Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 2Recruiting 2Not yet recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 1780Triple Negative Breast Neoplasms 299Ovarian Neoplasms 136Lung Neoplasms 115Colorectal Neoplasms 115Neoplasms 106Prostatic Neoplasms 103Carcinoma, Non-Small-Cell Lung 101Neoplasm Metastasis 96Stomach Neoplasms 81Pancreatic Neoplasms 78Melanoma 74Endometrial Neoplasms 65Head and Neck Neoplasms 60Uterine Cervical Neoplasms 56Squamous Cell Carcinoma of Head and Neck 50Colonic Neoplasms 45Esophageal Neoplasms 42Sarcoma 41Carcinoma, Intraductal, Noninfiltrating 41Motor Activity 37HER2-positive Breast Cancer 34Urinary Bladder Neoplasms 33Liver Neoplasms 31Carcinoma, Renal Cell 30Brain Neoplasms 28Advanced Breast Cancer 25Lymphedema 24Kidney Neoplasms 24Carcinoma, Transitional Cell 23

Interventions

pyrotinib 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Advanced Breast Cancer × Breast × Clear all
NCT07047365 2026-06-03

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
416 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT05856383 2023-05-12

HER2-VIP

Zhejiang Cancer Hospital

Recruiting
100 enrolled
Breast

HER2-positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡